15 results about "Serum lipid levels" patented technology

This invention provides a *Lactobacillus plantarum* LN-Lp1 strain, its applications, products, and methods, belonging to the field of probiotic technology. The *Lactobacillus plantarum* LN-Lp1 strain has the accession number CGMCC 33158. This LN-Lp1 strain was deposited on December 23, 2024, at the China General Microbiological Culture Collection Center, located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing. Based on this strain, this invention also provides its uses and related products. This LN-Lp1 strain exhibits strong resistance to simulated gastric-intestinal stress and good intestinal adhesion and colonization potential. The *Lactobacillus plantarum* LN-Lp1 of this invention has excellent weight-loss effects, improving lipid metabolism and lowering blood lipid levels.

The application discloses medical use of gelated cells loaded with sulfonated chitosan in treatment of atherosclerosis, and belongs to the technical field of biological medicine. The gelated cells loaded with sulfonated chitosan take macrophages as host cells, and intracellular cross-linking forms a photocrosslinking hydrogel network composed of methacrylated hyaluronic acid and sulfonated chitosan. The gelated cells completely retain cell membrane structure and membrane surface protein expression, lose the proliferation ability, and have excellent blood lipid selective adsorption capacity and foam cell lipid metabolism regulation capacity. In-vivo and in-vitro experiments prove that the gelated cells can significantly reduce blood lipid levels of atherosclerosis model animals, reduce aortic plaque area, and have good biological safety, thereby providing a new strategy and candidate drug for prevention and treatment of atherosclerosis, and having a good clinical application prospect.

The present application relates to the field of traditional Chinese medicine compound, disclose a kind of traditional Chinese medicine compound for treating fatty liver, its raw material composition by mass ratio is: Gynostemma pentaphyllum 28~32, including 13~17, Cassia obtusifolia 11~14, turmeric 6~12, red yeast 7~11.The traditional Chinese medicine compound of the present application-Jianyu Xiaozhi recipe, with the effect of transporting spleen and soothing heart, resolving turbidity and removing blood stasis, the curative effect is remarkable, not only significantly reduce the body mass index and blood lipid level of NASH patient, also can improve liver damage and fibrosis degree.

The present disclosure relates to a use of Lacticaseibacillus rhamnosus FMBL L23004 CNN in the preparation of a medicament for preventing or treating diabetes mellitus. The Lacticaseibacillus rhamnosus FMBL L23004 CNN was deposited with the China Center for Type Culture Collection (CCTCC) on 26 Jun. 2023 under the accession number CCTCC NO: M 20231099. The Lacticaseibacillus rhamnosus FMBL L23004 CNN strain has the effect of inhibiting the activity of α-glucosidase, α-amylase, and dipeptidyl peptidase IV. Administration of the strain can significantly lower oral glucose tolerance and insulin tolerance in Type 2 Diabetes Mellitus (T2DM) mice, reduce abnormal postprandial blood glucose fluctuations, decrease fasting blood glucose levels, lower fasting insulin levels, reduce blood lipid levels, and alleviate insulin resistance. The strain significantly improves the composition of the gut microbiome, increases the abundance and diversity of beneficial gut bacteria, and reduces the relative abundance of pathogenic bacteria.

This invention belongs to the technical field of natural product active ingredients, specifically relating to a glycopeptide LBGP-I-b derived from wolfberry and its uses. The glycopeptide LBGP-I-b has an average molecular weight of 700–1000 Da, a polypeptide content of 70%–80%, and a polysaccharide content of 10%–20%. The sugar chains are composed of glucose residues, and the sugar chains are linked to the peptide chains via O-glycopeptide bonds. The glycopeptide has functions such as regulating lipid metabolism, lowering blood lipid levels, and improving liver function. The glycopeptide of this invention has a clear source and stable properties, and has good application prospects in the prevention and treatment of metabolic diseases such as metabolic-related fatty liver disease.

The present invention relates to an immunogenic compound comprising an ApoB100 epitope, an immunogenic composition comprising the same, and uses thereof. The immunogenic compound can be used to prevent or treat diseases caused by increased ApoB100 levels or increased lipid levels by inducing an immune response to the ApoB100 epitope. The immunogenic compound has a complementary mechanism to GIP-1R agonist obesity treatments, so their combined or concurrent administration can enhance weight loss and improve side effects associated with long-term administration of GIP-1R agonist obesity treatments by improving weight loss plateaus, delaying the yo-yo effect, and improving lean body mass reduction.

The application provides a lactobacillus sakei LN-Ls1 with weight loss and lipid-lowering effects and an application thereof, and belongs to the technical field of microorganisms. The lactobacillus sakei LN-Ls1 has a preservation number of CGMCC 30611. The LN-Ls1 strain is preserved in the China General Microbiological Culture Collection Center on May 13, 2024, and the address is No. 1, Beichen West Road, Chaoyang District, Beijing. Based on the strain, the application also provides the use and related products thereof. The lactobacillus sakei LN-Ls1 can significantly reduce body weight, improve blood lipid level and lipid metabolism without affecting food intake, has a remarkable weight loss and lipid-lowering effect, and has a better technical effect compared with existing products, and has good safety and application prospect.

The present application relates to a sustained-release pharmaceutical composition of GLP-1 receptor agonist and a preparation method thereof. The composition comprises 0.05-0.5 wt% active ingredient, 45-85 wt% sustained-release agent, and 15-55 wt% viscosity reducer, or comprises 0.05-0.5 wt% active ingredient and 45-99.95 wt% thermal sensitive sustained-release agent. The active ingredient is GLP-1 receptor agonist, the sustained-release agent is polyorthoester, and the viscosity reducer is preferably glycerate compound. The present application also provides a pharmaceutical combination product comprising the sustained-release pharmaceutical composition, and application of the composition in treating metabolic related diseases. The sustained-release pharmaceutical composition has significantly improved pharmacokinetic characteristics, can realize long-acting administration, improve patient compliance, and shows excellent effects in improving blood glucose control, promoting weight loss, and improving blood lipid level.

Provided are a sustained-release pharmaceutical composition of a GLP-1 receptor agonist and a preparation method therefor. The composition contains 0.05 wt% to 0.5 wt% of an active ingredient, 45 wt% to 85 wt% of a sustained-release agent, and 15 wt% to 55 wt% of a viscosity-reducing agent, or contains 0.05 wt% to 0.5 wt% of an active ingredient, and 45 wt% to 99.95 wt% of a thermal sensitive sustained-release agent, wherein the active ingredient is a GLP-1 receptor agonist, the sustained-release agent is a polyorthoester, and the viscosity-reducing agent is preferably a glyceryl ester compound. Further provided are a drug-medical device combination product containing the sustained-release pharmaceutical composition, wherein the drug is the above-described sustained-release drug, and the medical device is a jet microneedle capable of injecting high-viscosity substances, and the use of the composition in the treatment of metabolism-related diseases. The sustained-release pharmaceutical composition has significantly improved pharmacokinetic characteristics, can realize long-acting administration, improves patient compliance, and exhibits good effects in improving blood glucose control, promoting weight loss, improving blood lipid levels, etc.

The application discloses application of a water-soluble tomato extract in preparation of a blood lipid-lowering composition, and belongs to the technical field of functional food, and comprises the following components in mass parts: water-soluble tomato extract 50-100 parts, morchella esculenta extract 30-50 parts, catalpa seed extract 20-30 parts, ampelopsis grossedentata extract 5-10 parts, bitter gourd extract 5-10 parts, green tea extract 5-10 parts, rye ferment 20-30 parts and white kidney bean extract 10-20 parts. The application takes the water-soluble tomato extract as a main raw material, and is compounded with various plant extracts which are edible and medicinal, and each component plays a synergistic role in three levels of intestinal tract, cells and organs to reduce blood lipid level. The application solves the problem that in the prior art, due to single action target point of blood lipid-lowering products and side effect risk, it is difficult to realize multi-target point synergistic regulation of blood lipid and the safety is limited, and has application potential in preparation of blood lipid-lowering functional food.

Provided are the use of Collinsella shenzhenensis in treating and / or preventing inflammation-related diseases, cardiovascular diseases, and a composition for treating and / or preventing inflammation-related diseases, cardiovascular diseases, including a pharmaceutical product, a beverage, a food product, or an animal feed composition, etc., and a method for improving intestinal lesions of a mammal, reducing blood lipid levels of a mammal, controlling weight loss of a mammal, and / or reducing disease activity index (DAI) of a mammal.

The application belongs to the technical field of natural medicinal chemistry and enzyme inhibitor development, and particularly relates to a preparation method and application of an active ingredient of red bean. The active ingredient is (+) catechin 7-O-beta-D-glucopyranoside accurately separated from red bean. In vitro experiments prove that the active ingredient has strong inhibitory effect on alpha-glucosidase and pancreatic lipase. Cell and animal experiments further prove that the active ingredient can significantly inhibit the differentiation and lipid accumulation of 3T3-L1 preadipocytes, and can effectively reduce the body weight, body fat and blood lipid level of high-fat diet induced obese mice, and improve liver steatosis. The application plays a multi-target anti-obesity effect by synergistically inhibiting the digestion and absorption of sugar and fat, and has a wide application prospect in the preparation of medicines and functional foods for preventing and treating obesity, type II diabetes and other metabolic diseases.

The present application provides a traditional Chinese medicine composition for treating and / or preventing coronary heart disease, and a preparation method and application thereof. Specifically, the traditional Chinese medicine composition of the present application is prepared from raw materials comprising the following components: 8-13 parts of capillaris, 8-12 parts of atractylodes, 8-12 parts of alisma, 8-14 parts of curcuma, 10-20 parts of salvia, 8-14 parts of curcuma, 1-5 parts of panax notoginseng powder, 5-10 parts of rhizoma corydalis, 8-12 parts of pinellia, 5-10 parts of berberis, 4-10 parts of ginseng, 5-12 parts of dried tangerine or orange peel, and 4-10 parts of licorice. The present application also provides a method for preparing the traditional Chinese medicine composition of the present application and the use of the traditional Chinese medicine composition in preparing a medicine for treating and / or preventing coronary atherosclerotic heart disease. The traditional Chinese medicine composition of the present application can reduce blood viscosity, improve heart function, reduce myocardial infarction area, inhibit the formation of atherosclerotic plaques, regulate blood lipid levels, or reduce the level of myocardial injury markers in serum.

This invention relates to a morel lectin, its preparation method, and its application, belonging to the field of biotechnology. The amino acid sequence of the morel lectin of this invention is shown in SEQ ID NO.1. The morel lectin is obtained by ultrafiltration, saturated ammonium sulfate precipitation, dialysis, microporous membrane filtration, Q Beads 6FF ion chromatography, dialysis, and freeze-drying of the supernatant after homogenizing morel mushrooms with water. The morel lectin is used to treat non-alcoholic fatty liver disease (NAFLD), inhibiting weight gain, reducing hepatomegaly, lowering blood lipid levels, improving obesity symptoms, reducing hepatic steatosis and liver function damage, and effectively treating NAFLD.

The present application relates to the use of parvuline in the preparation of a weight loss drug. It has been found that parvuline B can reduce the weight of mammals. Further research has found that it can reduce the weight of mammals because it mainly reduces the blood lipid level and the lipid accumulation in adipocytes by hydrolyzing the triglyceride in adipocytes into free fatty acid and glycerol through enhancing the activity of key rate-limiting enzyme responsible for lipid metabolism in adipocytes, thereby reducing the mass of adipose tissue to achieve weight loss.